Asterias Biotherapeutics, Inc., a leading biotechnology company in the emerging field of regenerative medicine, today announced today that it has priced an underwritten public offering of its common stock at a price of $3.90 per share.
from The Medical News http://ift.tt/1BZMAnC
from The Medical News http://ift.tt/1BZMAnC
No comments:
Post a Comment